奥翔药业两款原料药上市申请获批 进一步丰富产品线

Group 1 - Aoxiang Pharmaceutical has received approval from the National Medical Products Administration for the marketing of palbociclib and dagagliflozin active pharmaceutical ingredients [1] - Palbociclib is the first CDK4/6 inhibitor approved for cancer treatment, specifically for HR+ positive and HER2- negative locally advanced or metastatic breast cancer, with a projected global sales of approximately $4.367 billion in 2024 [1] - Dagagliflozin is a new oral hypoglycemic agent that can improve blood sugar control and reduce cardiovascular risks in heart failure patients, with an expected global sales of about $7.72 billion in 2024 [1] Group 2 - Aoxiang Pharmaceutical provides non-patent infringing process design, development, and regulatory submission services for generic drug manufacturers, gaining recognition in regulated markets like the US, Europe, and Japan [2] - The raw material drug sector is considered a core part of the pharmaceutical industry, with the quality of raw materials directly impacting the safety and efficacy of final drugs [2] - The trend of developing countries like China and India improving their raw material drug capabilities is evident, with advancements in research and production technology [2] Group 3 - R&D innovation is crucial for the sustainable development of pharmaceutical companies in China, especially in the face of challenges like patent expirations and centralized procurement [3] - Optimizing processes and enhancing quality for generic raw materials is essential for Chinese pharmaceutical companies to transition towards high-end specialty raw materials and innovative drugs [3]